These provided the initial clinical proof-of-concept and validation of HSP90 as a cancer target but generally showed modest efficacy and were limited by unfavorable properties, particularly liver toxicity, most likely due to the quinone moiety (Banerji, 2009; Garcia-Carbonero et al., 2013). Here, HSP90AB1 is linked to cancer.